Ying Bian

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

April, 2025

Ying Bian

Apr 4, 2025, 20:29 | Science

Gaëlle Saint-Hilary: Benefit-risk assessment of ivosidenib vs. placebo in mIDH1 cholangiocarcinoma

Gaëlle Saint-Hilary, CEO, Statistical methodologist at Saryga, shared a post on LinkedIn about a paper…

All: 1 Posts: 1 - 100

'

ASCO 2025 for Trainees and Residents: Your Ultimate Guide to Success

'

ctDNA after surgery for MMRd tumors can prevent cancer recurrence - Yelena Janjigian at AACR25

'

Top Growing Medical Universities in the Post-Soviet Region – BIGR 2025 Edition

'

Organ Preservation in dMMR Tumors: Results from Neoadjuvant Phase II Study with Dostarlimab

'

POEM 2025 Scientific Meeting: Key Sessions, Workshops, and Why You Should Attend

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023